With commercial approval rates as low as 10% for gene therapies and 17% for cell therapies at Phase 1, the stakes for early development are high.*
While many factors contribute to this considerable attrition, challenges associated with progressing innovative R&D processes to standardized and robust manufacturing methods are a driving force. Platform processes for cell and gene therapies (CGTs) have emerged as potential solutions to streamline development, but they may impose restrictive protocols that can stifle innovation and result in suboptimal outcomes.
As an alternative to this traditional approach, Thermo Fisher Scientific has developed the Rapid Development Framework™ solutions to accelerate the development and manufacturing of cell therapies and viral vectors while remaining adaptable to the unique needs of each product. These frameworks enable control over your processes while leveraging standardized elements for improved efficiency and reliability—transforming the way CGTs are brought to market.